Foxiga Korea Local Phase 4 Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

Also called NCT02564926

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02564926
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02564926. Randomized; no masking; primary purpose treatment. Start 2016-01-05 (actual); primary completion 2018-01-15 (actual). Results posted on 2019-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Foxiga Korea Local Phase 4 Study
Acronym
BEYOND
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Glimepiride
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02564926
Content hash
d69ecf2d17589f31a9e837e3ed0ce9c3fe5b68af71506be9f5d0f15bc40f728b